Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

1The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia

2Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

3Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California

4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

5Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

6Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia

7NHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia

8Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California

9Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia

10Charité Lab for Artificial Intelligence in Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany

11QUEST Center for Transforming Biomedical Research, Berlin Institute of Health (BIH), Berlin, Germany

12Complications Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark

13Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

14National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico

15Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas

16Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts

17Department of Renal Medicine, University College London, London, United Kingdom

18Royal North Shore Hospital, Sydney, New South Wales, Australia

Correspondence: Dr. Brendon L. Neuen, The George Institute for Global Health, Level 5, 1 King Street Newtown, Sydney, NSW 2042, Australia. Email: [email protected]

Comments (0)

No login
gif